Health TechnologyMay 25, 2026·5 min read
By the CIRRUS Editorial Team — how we write and source this
Pharmacogenomic testing: how genetics can predict medication response and side effects
Certain gene variants measurably change how people metabolize common drugs — testing for them is moving from research into routine clinical use for specific medication classes.
Pharmacogenomic testing analyzes specific gene variants, particularly in liver enzymes like the CYP450 family, that determine how quickly an individual metabolizes many common medications — variants that classify people as poor, intermediate, normal, or rapid metabolizers for specific drug classes, which directly affects both efficacy and side effect risk at a standard dose.
The clinical applications with the most established evidence and guideline support include certain antidepressants and antipsychotics (where metabolizer status affects both efficacy and side effect risk), some blood thinners like warfarin (where genetic variants affect the dose needed for stable anticoagulation), and specific cancer chemotherapy drugs where certain variants create serious toxicity risk at standard doses.
This is a different, more clinically validated category than the broader direct-to-consumer genetic wellness testing market — pharmacogenomic testing for specific drug-gene pairs with established clinical guidelines (maintained by resources like CPIC) has real actionable value, and is increasingly used by psychiatrists and oncologists specifically to guide initial dosing decisions rather than relying solely on trial-and-error titration.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.